Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Efficacy in High-Risk CLL and SLL

April 12th 2022

The combination of ibrutinib and venetoclax administered for a fixed duration elicited durable responses and sustained progression-free survival in previously untreated, high-risk patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from the phase 2 CAPTIVATE trial.

Final Response Analysis of ALPINE Trial Shows Superior ORR With Zanubrutinib Vs Ibrutinib in CLL

April 11th 2022

Zanubrutinib demonstrated superiority over ibrutinib in terms of overall response rate per independent review committee assessment in adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Genomic Analyses Shed Light on Mechanisms of Resistance to Noncovalent BTK Inhibitors in Relapsed/Refractory CLL

April 7th 2022

Justin W. Taylor, MD, discusses the significance of BTK inhibition in the treatment of patients with CLL, the genomic analyses conducted in those enrolled to BRUIN who received pirtobrutinib, and the significance of the data yielded from this research.

Venetoclax Consolidation Does Not Prevent Loss of MRD Response Following First-Line Venetoclax/Obinutuzumab for CLL

April 7th 2022

Venetoclax consolidation following first-line treatment with venetoclax and obinutuzumab did not reduce loss of minimal residual disease response vs MRD-guided venetoclax consolidation in previously untreated patients with chronic lymphocytic leukemia.

Movement of Novel Agents Up Front Is Current Focus in Hematologic Cancers

April 6th 2022

Ann S. LaCasce, MD, MMSc, discusses updates in lymphoma, myelofibrosis, and chronic lymphocytic leukemia.

BTK- and Venetoclax-Based Approaches Move the Needle Forward in CLL Management

April 5th 2022

Inhye Ahn, MD, discusses the evolving treatment landscape of chronic lymphocytic leukemia, the advances made with BTK inhibitors and venetoclax-based regimens, novel combination regimens under exploration, and other research efforts that are underway.

Fixed-Duration Therapy Struggles to Find Footing Across Tumor Types

March 28th 2022

Fixed-duration systemic therapies have gained some traction in hematologic malignancies, where advances in drug development and sequencing strategies have afforded investigators the opportunity to conduct trials.

Optimizing the Treatment of CLL With Novel Therapies

March 14th 2022

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.

CAR T-Cell Therapies in CLL

March 14th 2022

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

PI3K Inhibitors for CLL

March 7th 2022

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

Noncovalent BTK Inhibitors in CLL

March 7th 2022

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

FDA Extends PDUFA Date for BLA/sNDA of Ublituximab Plus Umbralisib in CLL/SLL

March 3rd 2022

The FDA has extended the Prescription Drug User Fee Act goal date for the biologics license application and supplemental new drug application seeking the approval of ublituximab plus umbralisib in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Burger on the Current Landscape of CAR T-Cell Therapy in CLL

March 1st 2022

Jan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.

Dr. Oh on the Evolving Treatment Landscape in CLL

February 24th 2022

Stephen Oh, MD, PhD, discuses the evolving treatment landscape of chronic lymphocytic leukemia.

Dr. Kahl on the Potential of Zanubrutinib in the Frontline Treatment of CLL

February 24th 2022

Brad S. Kahl, MD, discusses the potential for zanubrutinib in the frontline treatment of chronic lymphocytic leukemia.

Zanubrutinib Applications for CLL and MZL Accepted for Review in Europe

February 23rd 2022

The European Medicines Agency has accepted for review 2 new indication applications for zanubrutinib as a therapeutic option for patients with chronic lymphocytic leukemia and for those with marginal zone lymphoma.

FDA Accepts sNDA for Zanubrutinib in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

February 23rd 2022

The FDA has accepted for review a supplemental new drug application for zanubrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Treating CLL With Anti-CD20 Antibody Regimens

February 21st 2022

Recommendations for combining an anti-CD20 antibody with a Bruton tyrosine kinase inhibitor or venetoclax in doublet or triplet regimens for the treatment for chronic lymphocytic leukemia (CLL).

Chemotherapy-Free Regimens as Frontline Therapy in CLL

February 21st 2022

Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.

Q and A Session

February 18th 2022

Amy Goodrich, RN, MSN, CRNP, and Kirollos S. Hanna, PharmD, BCPS, BCOP, answer audience questions regarding CLL and BTK inhibitors during a question & answer session.